Australia's most trusted
source of pharma news
Posted 22 December 2021 AM
Moderna has unveiled a two-pronged approach to defeat the Omicron variant, using its current vaccine as a powerful third dose while simultaneously advancing an Omicron-specific booster to clinical trials in case it becomes necessary.
As the new variant - which was first reported to the World Health Organisation just 28 days ago - sweeps the globe, Moderna has released encouraging results for its COVID-19 vaccine, Spikevax.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.